Position in AVXL
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$166,200
+$13,633 QoQ
Shares Held
54,137
+26.3% QoQ
Ownership
0.058%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in AVXL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cetera Investment Advisers holds $158,169,500 across 104 Biotechnology names. AVXL ranks #65 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
72,633 | $32,433,539 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,006 | $12,366,875 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
23,173 | $7,667,250 | |
| 4 | EXEL |
Exelixis, Inc.
|
169,881 | $7,286,196 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
946,709 | $7,261,258 | |
| 6 | OCUL |
Ocular Therapeutix, Inc
|
764,615 | $6,476,289 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
189,028 | $6,150,971 | |
| 8 | INSM |
INSMED Inc
|
34,356 | $5,617,893 |
All Filings in AVXL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $166,200 | 54,137 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $152,567 | 42,856 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $251,496 | 28,258 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $145,878 | 15,822 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $172,106 | 20,059 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $150,370 | 14,001 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||